Differential impact of milvexian, an investigational oral FXIa inhibitor vs apixaban and dabigatran on thrombin generation in human donor plasma in vitro

Back

ESC Professional Premium Access

Differential impact of milvexian, an investigational oral FXIa inhibitor vs apixaban and dabigatran on thrombin generation in human donor plasma in vitro

Session: Clinical and basic science insights in vascular disease

Topic: Thrombosis, Bleeding

Speaker: Doctor M. Chintala (Spring House, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Madhu Chintala

Spring House (United States of America)

1 follower

6 more presentations in this session

Genome-wide association study on cerebral white-matter hyperintensities in 36,577 individuals

Speaker: Mr J. Jespersen (Copenhagen, DK)

Access

Abstract

Slides

DNA damage induced by radiation exposure from cardiac catheterization - an analysis in patients and operators

Speaker: Doctor T. Ishida (Fukushima, JP)

Access

Abstract

Slides

SWATH proteomic analysis from the standard care versus celecoxib outcome trial identifies renal biomarkers are associated with early cardiovascular events amongst NSAID users

Speaker: Doctor R. Vaja (London, GB)

Access

Abstract

Slides

Preservation of vasculature is beneficial in mitigating cisplatin induced acute kidney injury

Speaker: Associate Professor H. Pan (Saint Louis, US)

Access

Abstract

Slides

Lack of PI 3-kinase isoform p110alpha impairs SMC differentiation and proliferation and promotes aortic aneurysm formation

Speaker: Doctor M. Vantler (Cologne, DE)

Access

Abstract

Slides

Access the full session

Clinical and basic science insights in vascular disease

Speakers: Doctor M. Chintala, Mr J. Jespersen, Doctor T. Ishida, Doctor R. Vaja, Associate Professor H. Pan...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources